Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 May 6;10(5):e0123600. doi: 10.1371/journal.pone.0123600

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 Kleczko et al

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.

PMC Copyright notice

Fig 1 — RNA and protein was isolated from UMSCC25, 584-A2, and Ca9-22 HNSCC cell lines that were treated for 4 days with DMSO (control), 0.3M AZD8010, 0.1M gefitinib, or both AZD8010 and gefitinib. RNA was submitted to an Affymetrix GeneChip analysis and revealed 5 genes that were upregulated in common with AZD8010 and gefitinib. The genes identified had either a >2 (UMSCC25 and Ca9-22) or >1.5 (584-A2) fold change in expression levels compared to the DMSO control. A. A venn diagram showing the genes upregulated in all the cell lines. B. Tabulated values for the genes increased and decreased in the AZD8010 and gefitinib treated group. *Numbers are the fold change in the treated compared to the control. TKIs: AZD8010 is an FGF receptor inhibitor and gefitinib is an EGF receptor inhibitor.